Lentiviral LDLR Vectors for Stable Liver Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for familial hypercholesterolemia, particularly in homozygous patients, are only partially effective and associated with significant side effects, while existing gene therapy options like AAV vectors face limitations in long-term stability and efficiency, especially in rapidly dividing tissues.
Innovation Solution
Development of lentiviral vectors encoding LDLR, engineered for liver-specific expression using transcriptional and post-transcriptional regulation, and optimized to lack MHC and enhance CD47 expression, allowing stable transgene expression in hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for LDLR gene transfer, then initial cholesterol reduction is achieved, but long-term stability is lost due to episomal loss during liver growth
Solution Approach 1:
The patent changes the fundamental parameter of vector integration mechanism from episomal (AAV) to genomic integration (lentiviral), transforming the stability profile to maintain persistent expression through cell divisions in growing livers
Solution Approach 2:
The patent introduces lentiviral vectors as an intermediary carrier that enables stable genomic integration of the LDLR transgene, serving as a bridge between initial cholesterol reduction and long-term stable expression in pediatric patients
2Reliability
If conventional lentiviral vectors are used, then integrating gene transfer is achieved, but production of sufficient titers is problematic
Solution Approach 1:
The patent optimizes production parameters including cell line selection (HEK293FT), transfection conditions, and vector design to achieve high titers of integrating lentiviral vectors suitable for treating large animals and humans
Solution Approach 2:
The patent uses highly efficient production systems that generate sufficient copies of lentiviral vectors through optimized transfection and assembly processes, enabling therapeutic doses for human treatment
3Quantity of substance
If current cholesterol-lowering drugs are used in homozygous patients, then partial cholesterol reduction is achieved, but significant side effects occur and full normalization is not possible
Solution Approach 1:
The patent introduces lentiviral-mediated LDLR gene transfer as an intermediary therapeutic approach that restores physiological cholesterol clearance capacity, replacing the need for chronic drug therapy and avoiding associated side effects
Solution Approach 2:
The patent enables the patient's own hepatocytes to produce functional LDLR protein through gene transfer, allowing the body's natural cholesterol clearance mechanisms to function autonomously without continuous external drug intervention
Data Source
AI summary
A lentiviral vector comprising a nucleotide sequence encoding low density lipoprotein receptor (LDLR) operably linked to a promoter, optionally wherein the nucleotide sequence encoding LDLR and the promoter are in a reverse orientation in the lentiviral vector.